AbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society Meeting
MT newswire2026/10/09 15:2811:28 AM EDT, 10/09/2026 (MT Newswires) -- AbCellera Biologics (ABCL) said late Thursday it will present phase 1/2 data on ABCL635, its investigational antibody treatment for menopause-related hot flashes, at The Menopause Society's 2026 annual meeting in San Diego. The presentation will include safety, pharmacokinetic, pharmacodynamic and efficacy data, including new safety results from the phase 1 multiple ascending dose study and new patient-reported outcomes from the phase 2 trial. ABCL635 is being evaluated as a non-hormonal, long-acting treatment for moderate-to-severe vasomotor symptoms associated with menopause, the biotechnology company said. Shares of AbCellera Biologics were up more than 4% in Friday trading. Price: 12.60, Change: +0.58, Percent Change: +4.83
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forward Industries Adds 226,396 SOL as Solana Price Falls to $82
BUZZ - Capri shares fall after appointing new CEO
EUR/USD: Range persists as Dollar outperforms – Societe Generale
Crypto prices
More
